(MedPage Today) — The FDA expanded the indications for risankizumab (Skyrizi) in plaque psoriasis and psoriatic arthritis to include treatment of children 6 years and older, AbbVie announced.
An interleukin (IL)-23 antagonist, risankizumab is…
Source link : https://www.medpagetoday.com/dermatology/psoriasis/121968
Author :
Publish date : 2026-06-29 16:53:00
Copyright for syndicated content belongs to the linked Source.
